All In Biotech

Drug Trial Radar · NCT05924750

A Study of BL-M11D1 in Patients With Relapsed/Refractory Acute Myeloid Leukemia

A Phase I Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of BL-M11D1 in Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients

Last checked: Nov 19, 2026Latest source record: Sep 26, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

130

Planned (sponsor's estimate)

Start

Aug 2, 2023

Primary completion

Dec 2026

Study completion Dec 2027

Sponsor

Sponsor type
Industry
First posted
Jun 29, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Ia: To observe the safety and tolerability of BL-M11D1 in patients with relapsed/refractory acute myeloid leukemia to determine the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of BL-M11D1. Ib: Further observe the safety and tolerability of BL-M11D1 at the recommended dose in phase Ia to determine the recommended dose in phase II clinical study (RP2D).

Conditions

  • Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)

Interventions

  • BL-M11D1Drug

    Administration by intravenous infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase Ia: Dose limiting toxicity (DLT)Time frame: Up to 28 days after the first dose
  2. Phase Ia: Maximum tolerated dose (MTD)Time frame: Up to 28 days after the first dose
  3. Phase Ib: Recommended Phase II Dose (RP2D)Time frame: Up to 28 days after the first dose

Locations

8 sites in 1 country. Site status is shown where the registry gives one.

  • Anhui Provincial Hospital

    Hefei, Anhui, China · Not yet recruiting

  • Beijing Hospital

    Beijing, Beijing Municipality, China · Not yet recruiting

  • Institute of Hematology, the First Hospital of Harbin

    Haerbin, Heilongjiang, China · Not yet recruiting

  • Shengjing Hospital of China Medical University

    Shenyang, Liaoning, China · Not yet recruiting

  • Qilu Hospital of Shandong University

    Jinan, Shangdong, China · Not yet recruiting

  • Shanghai Tongji Hospital

    Shanghai, Shanghai Municipality, China · Not yet recruiting

  • West China Hospital,Sichuan University

    Chengdu, Sichuan, China · Not yet recruiting

  • Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences

    Tianjin, Tianjin Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.